Replies to post #273 on Fate Therapeutics Inc (FATE)

[NY1972]

CGEM MICA/B good enough for a poster. So much for the pan cancer claim. Not good news for NKTX.
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.